dlbcl

Showing 26 - 42 of 42

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • AUTO3
  • Duarte, California
  • +10 more
Nov 19, 2021

Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Nov 1, 2021

DLBCL Trial in Shanghai (IBI110 plus sintilimab, IBI110)

Not yet recruiting
  • DLBCL
  • Shanghai, Shanghai, China
    Ruijin Hospital affiliated to Shanghai Jiao Tong University Scho
Sep 1, 2021

Lymphoma, DLBCL, Follicular Lymphoma Trial in Belgium, France (Tazemetostat, Rituximab, Cyclophosphamide)

Recruiting
  • Lymphoma
  • +2 more
  • Bruxelles, Belgium
  • +30 more
Jul 23, 2021

DLBCL, Diffuse Large B Cell Lymphoma Trial in Worldwide (R-pola-mini-CHP, R-mini-CHOP)

Recruiting
  • DLBCL
  • Diffuse Large B Cell Lymphoma
  • Aalborg, Denmark
  • +44 more
Jul 8, 2021

DLBCL Trial in Rotterdam (R-DHAP, Brentuximab Vedotin)

Recruiting
  • DLBCL
  • R-DHAP
  • Brentuximab Vedotin
  • Rotterdam, Netherlands
    NL-Rotterdam-ERASMUSMC
Dec 9, 2020

Diet, Physical Activity and Body Composition Changes During

Withdrawn
  • Non-Hodgkin Lymphoma
  • +2 more
  • 24-hour dietary recall
  • +7 more
  • Washington, District of Columbia
    Milken Institute School of Public Health, George Washington Univ
Oct 2, 2020

DLBCL Trial (Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day

Approved for marketing
  • DLBCL
  • Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
  • (no location specified)
Aug 26, 2020

DLBCL Trial in Belgium, France (RCHOP21)

Completed
  • DLBCL
  • Antwerpen, Belgium
  • +82 more
Jul 10, 2020

SMOLY : Phenotype and Functions of Monocyte Subtypes in High

Completed
  • DLBCL
    • Rennes, Brittany, France
      Rennes Univeristy Hospital
    Nov 5, 2019

    Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma Trial in United States (SGN-CD19B)

    Terminated
    • Non-Hodgkin Lymphoma
    • +3 more
    • Birmingham, Alabama
    • +15 more
    Aug 9, 2018

    Advanced Cancers, DLBCL, Lymphoma Trial in United States (IONIS-STAT3Rx)

    Completed
    • Advanced Cancers
    • +2 more
    • Scottsdale, Arizona
    • +8 more
    Jun 20, 2018

    DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans

    Completed
    • DLBCL
      • Amiens, France
      • +16 more
      Apr 6, 2018

      DLBCL, MCL, Recurrent Disease Trial in Meldola (90Y-DOTATOC)

      Terminated
      • DLBCL
      • +2 more
      • Meldola, FC, Italy
        Nuclear Medicin Division, IRST IRCCS
      Mar 16, 2018

      DLBCL Trial in Hwasun-gun (Intrathecal methotrexate, High-dose intravenous methotrexate)

      Unknown status
      • DLBCL
      • Intrathecal methotrexate
      • High-dose intravenous methotrexate
      • Hwasun-gun, Jeollanam-do, Korea, Republic of
        Chonnam National University Hwasun Hospital
      Apr 21, 2017